Labcorp Holdings Inc. (LH) Stock Price & Analysis

Labcorp Holdings Inc. (LH) closed at USD 329.93 on Thursday, October 22, 2026, up 1.91% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 323.75; the Oct 22, 2026 session ranged USD 316.22–331.71 on volume of 961,890 shares. Market capitalization is $26.76B, with a 52-week range of USD 244.52–341.8 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.

Also available as compact Markdown for AI agents: nexqual.com/LH.md

Key facts (LH)

• Last four reported quarters (through Jun 30, 2026): revenue $14.3B, net income $1.00B (7.0% margin), free cash flow $1.16B (SEC filings).
• Valuation: P/E 26.7x (avg 32.5x at the last 3 fiscal year-ends), EV/EBITDA 14.8x, net debt $5.72B.
• 3 of 80 tracked superinvestors hold LH (13F, Q2 2026): 0 new, 0 added, 2 reduced, 1 unchanged.
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $5.0M; 2 not under a Rule 10b5-1 plan ($723K); 2 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.28 on a 1–5 scale) (18 analysts), mean target USD 345.13 (range 293–385).
• Total return with dividends: 1Y +17.4% vs S&P 500 +14.9%; 5Y +43.5% vs S&P 500 +80.3%.
• Next earnings: 2026-10-28, EPS estimate USD 4.64, revenue estimate $3.76B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LH)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (LH)

P/E 26.7x · P/S 1.9x · EV/EBITDA 14.8x · EV/Sales 2.3x · P/FCF 23.2x · P/B 3.1x · FCF yield 4.32% · Earnings yield 3.75% · Dividend yield (paid, TTM) 0.89% · Buyback yield (TTM) 2.62% · Net debt $5.72B · EV $32.5B

P/E at fiscal year-ends: Dec 2025 24.0x, Dec 2024 25.9x, Dec 2023 47.6x.

Superinvestors (SEC 13F-HR, Q2 2026) (LH)

3 of 80 tracked investors hold LH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (LH)

6 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (LH)

Consensus Buy (mean 2.28 on a 1–5 scale), 18 analysts; mean target USD 345.13 (low 293, high 385).

Rating changes, last 120 days:

Total return (dividends reinvested) (LH)

LH revenue by business segment (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

LH analyst estimates and revisions

LH options: expected move

Options price a move of about ±6.9% (±$22.90) by Nov 20, 2026, which includes earnings on Oct 28, 2026. Over the last 8 reports the stock moved ±3.6% on average.

30-day implied volatility 29.7% vs 21.2% realized over the last 30 trading days. Put/call ratio (volume) 8. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:38 UTC)

Technical Analysis (LH)

Nexqual's technical model rates LH "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.

Analyst Ratings (LH)

Wall Street analysts rate LH "Buy" based on 18 analysts, with a mean price target of USD 345.13 (range USD 293–385), per Nexqual as of October 23, 2026 at 10:38 UTC.

Earnings (LH)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:38 UTC.

Financials & Fundamentals (LH)

Source: Nexqual, October 23, 2026 at 10:38 UTC.

Financial Health Score (LH)

Nexqual rates Labcorp Holdings Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:38 UTC.

Ownership (LH)

Source: Nexqual, October 23, 2026 at 10:38 UTC.

Leadership (LH)

Labcorp Holdings Inc. is led by Adam H. Schechter, President, CEO & Chairman, per Nexqual as of October 23, 2026 at 10:38 UTC.

Major Backers & Investors (LH)

Notable institutional backers of Labcorp Holdings Inc. include Victory Capital Management Inc., Boston Partners, Allspring Global Investments Holdings, LLC, according to Nexqual as of October 23, 2026 at 10:38 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:38 UTC.

From Labcorp Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• The BLS business operates through the following core capabilities: Based on Company estimates, in 2025, the global pharmaceutical industry spent more than $200 billion on R&D.
• The Company relies on a combination of patents, trademarks, copyrights, trade secrets, and confidentiality and non‑competition agreements to establish and protect its proprietary technology.
• Dx provides broad patient access through strategically located service sites across the U.S., including more than 2,200 PSCs and more than 7,000 in-office phlebotomists located in customer offices and facilities.

Partnerships

• At the end of 2025, the Company had outstanding authorization from its Board to purchase up to $830.4 million maximum value of Common Stock.

Legal & Regulatory Risks (Item 1A, quoted)

• The Company could face significant monetary damages and penalties and/or exclusion from government programs if it violates anti-fraud and abuse laws.
• The Company's business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of, the law or regulations of CLIA, Medicare, Medicaid or other national, state, or local agencies in the U.S. and other countries where the Company operates laboratories.
• Compliance with these complex and evolving regulations may require changes to the Company's business practices and result in increased operational costs.
• The Company's international operations could subject it to additional risks and expenses that could adversely impact the business or results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt